Century Therapeutics cuts 51% of workforce; CFO and CDO to depart

Century Therapeutics, Inc.

Board approved reduction in force of ~51% of employees; expects $3.7M in severance costs.
CFO Morgan Conn to depart effective July 11; SVP Finance Douglas Carr named interim principal financial officer.
Chief Development Officer Adrienne Farid to depart effective July 31.
Workforce reduction substantially complete by end of Q3 2025; company focusing on highest-potential programs.

item 2.05item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.